• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

October 14, 2019
Company Drug/Device Medical Condition Status
Yumanity Therapeutics YTX-7739 Parkinson’s disease Phase 1 trial initiated enrolling 40 healthy subjects
Medivir AB birinapant and radiation therapy Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1 trial initiated enrolling subjects with recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Debiopharm Debio 1143, with Keytruda (pembrolizumab) Pancreatic and colorectal cancer Phase 1 trial initiated enrolling 46 subjects without other available therapeutic options
City of Hope chimeric antigen receptor (CAR) T cells in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) glioblastoma Phase 1 trial initiated
Hutchinson China MediTech Limited HMPL-523 relapsed or refractory lymphoma Phase 1/1b trial initiated doising subjects with relapsed or refractory lymphoma at sites in the U.S. and Europe
Nektar Therapeutics NKTR-358 (LY3471851) psoriasis Phase 1b trial initiated enrolling 40 subjects with plaque psoriasis
Nektar Therapeutics NKTR-358 (LY3471851) atopic dermatitis Phase 1b trial initiated enrolling 40 subjects with atopic dermatitis
DURECT Corporation DUR-928 non-alcoholic steatohepatitis (NASH) Phase 1b trial initiated enrolling 60 subjects with non-alcoholic steatohepatitis (NASH) with stage 1-3 fibrosis at multiple centers in the U.S.
AVROBIO, Inc. investigational gene therapy cystinosis Phase 1/2 trial initiated four adult subjects and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine at UC San Diego
IDEAYA Biosciences, Inc. cutaneous melanoma harboring a GNAQ or GNA11 (GNAQ/11) mutation solid tumors Phase 1/2 trial initiated
Minoryx Therapeutics MIN-102 Friedreich’s Ataxia Phase 2 trial initiated enrolling 39 subjects ages 12-60 with Friedreich’s Ataxia in four European countries
Oncologie bavituximab in combination with KEYTRUDA (pembrolizumab) gastroesophageal cancer Phase 2 trial initiated enrolling 80 subjects with advanced gastric or gastroesophageal cancer in the U.S., UK, South Korea and Taiwan
Frequency Therapeutics FX-322 Sensorineural Hearing Loss (SNHL) Phase 2a trial initiated enrolling 96 adult subjects ages 18 to 65 with stable SNHL at 12 sites in the U.S.
DURECT Corporation topical DUR-928 mild to moderate plaque psoriasis Phase 2a trial enrolling 20 subjects in the U.S.
Graybug Vision, Inc. GB-102 wet age-related macular degeneration (AMD) Phase 2b trial initiated enrolling 160 subjects with wet AMD at more than 100 sites in the U.S.
iLiAD Biotechnologies, LLC BPZE1 pertussis Phase 2b trial initiated enrolling 300 healthy subjects
Dermira, Inc. lebrikizumab moderate to severe atopic dermatitis Phase 3 trial initiated enrolling 800 adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis at 200 sites in the U.S., Europe and Asia
Galderma nemolizumab moderate to severe atopic dermatitis Phase 3 trial initiated
Seattle Genetics, Inc. tucatinib in combination with ado-trastuzumab emtansine (T-DM1, Kadcyla) breast cancer Phase 3 trial initiated enrolling up to 460 subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Beckman Coulter, Inc. DxA 5000 pre-analytical sample quality detection 510 (k) clearance granted by the FDA
Frequency Therapeutics FX-322 sensorineural hearing loss (SNHL) Fast Track designation granted by the FDA
Novartis Beovu (brolucizumab-dbll) wet age-related macular degeneration (AMD) Approval granted by the FDA
Clinuvel Scenesse (afamelanotide) erythropoietic protoporphyria (EPP) Approval granted by the FDA
Gilead Descovy HIV pre-exposure prophylaxis Approval granted by the FDA
AstraZeneca FASENRA pen (benralizumab) severe eosinophilic asthma Approval granted by the FDA
Galderma AKLIEF (trifarotene) Cream acne Approval granted by the FDA
Octapharma USA WILATE hemophilia A Approval granted by the FDA

 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing